Viyash Scientific shares demonstrated strong momentum in today's trading session, opening at ₹253.25 and reaching a high of ₹261.35 with a low of ₹253.00. The stock's average traded price for the day was ₹258.46, showing positive investor sentiment. Technical indicators suggest the stock is in an uptrend with the 50 DMA at ₹260.52 and 200 DMA at ₹221.89. As per latest market data, the stock was trading at ₹259.70 at 3:31 p.m. on July 27, 2026, reflecting continued positive momentum in the pharmaceutical sector.
Systematix has issued a Buy recommendation for Viyash Scientific with a target price of ₹290, representing significant upside potential from the current market price. The broker's recommendation is based on the company's strong profitability and strategic growth initiatives following the successful integration of multiple business units. With the stock's recent performance showing positive momentum, the recommendation appears well-timed as investors continue to show interest in the pharmaceutical company's diversified portfolio.
The company's FY26 annual report highlights the successful integration of the erstwhile Viyash LifeSciences, Sequent Scientific and Appco Pharma businesses, as reported by The Hindu BusinessLine. This strategic consolidation has resulted in profitability supported by operational turnaround across key subsidiaries and an improving business mix. The integration has positioned the company for enhanced operational efficiency and market presence across its diversified pharmaceutical portfolio, contributing to the positive investor sentiment reflected in today's trading performance.
Appco Pharma (US) emerged as the single largest earnings driver, contributing nearly 40 per cent of consolidated profit following a sharp turnaround in profitability, according to The Hindu BusinessLine. The Animal Health business witnessed broad-based improvement, with Alivira Animal Health significantly reducing losses. The company continued shifting its Human Formulations portfolio towards complex generics and differentiated products, supported by approximately 85 per cent backward integration across key products, which has been instrumental in driving the company's overall profitability and growth trajectory.
Revenue quality improved with PLI incentives and licensing income contributing ₹60.90 crore, as reported by The Hindu BusinessLine. Manufacturing investments continued with the gross block increasing to ₹1,820 crore. The company expanded its Companion Animal franchise through new product launches, strategic partnerships and dedicated R&D investments, positioning itself for sustained growth in the pharmaceutical sector. These strategic investments have contributed to the company's operational efficiency and market positioning across multiple pharmaceutical segments.
Governance remained largely comfortable with no material related-party transactions involving KMP-controlled entities, according to The Hindu BusinessLine. However, Dr Haribabu Bodepudi's remuneration of ₹78 crore and select transactions with Piramal Pharma Ltd and Aterna Labs Pvt Ltd represent key annual report observations that investors should monitor. The company's shareholding pattern shows promoters holding 61.31% as of March 2026, with Domestic Institutional Investors at 20.52% and Foreign Institutional Investors at 4.50%, indicating strong domestic institutional confidence in the pharmaceutical company's growth prospects.
